A new peg-filgrastim biosimilar, mecapegfilgrastim for primary prophylaxis of chemotherapy-related neutropenia is now available

Affiliations

¹ Centro di Riferimento Oncologico, Istituto Nazionale Tumori, IRCCS, Aviano (PN), Italy.
² Italian Association of Pharmacogenomics and Molecular Diagnostics (IAPharmagen), Ancona, Italy.
³ Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, IRCCS, Aviano (PN), Italy.

Editorial

Umberto Tirelli et al. Ann Transl Med. 2020 Mar.

. 2020 Mar;8(5):166.

doi: 10.21037/atm.2019.10.61.

¹ Centro di Riferimento Oncologico, Istituto Nazionale Tumori, IRCCS, Aviano (PN), Italy.
² Italian Association of Pharmacogenomics and Molecular Diagnostics (IAPharmagen), Ancona, Italy.
³ Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, IRCCS, Aviano (PN), Italy.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial.
Xu F, Zhang Y, Miao Z, Zeng X, Wu B, Cai L, Liu J, Wang S, Hu X, Zheng W, Chen Z, Yang Q, Jiang Z. Xu F, et al. Ann Transl Med. 2019 Sep;7(18):482. doi: 10.21037/atm.2019.07.95. Ann Transl Med. 2019. PMID: 31700918 Free PMC article.

1. Bonadonna G. Does chemotherapy fulfill its expectations in cancer treatment? Ann Oncol 1990;1:11-21. 10.1093/oxfordjournals.annonc.a057665 - DOI - PubMed
1. Kuwabara T, Kobayashi S, Sugiyama Y. Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor. Drug Metab Rev 1996;28:625-58. 10.3109/03602539608994020 - DOI - PubMed
1. Balducci L, Al-Halawani H, Charu V, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 2007;12:1416-24. 10.1634/theoncologist.12-12-1416 - DOI - PubMed
1. Hecht JR, Pillai M, Gollard R, et al. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer 2010;9:95-101. 10.3816/CCC.2010.n.013 - DOI - PubMed
1. Burris HA, Belani CP, Kaufman PA, et al. Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non–small-cell lung cancer, ovarian cancer, and non-hodgkin’s lymphoma: results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract 2010;6:133-40. 10.1200/JOP.091094 - DOI - PMC - PubMed